Bioventus Inc. reported second quarter 2026 revenue of $153.2 million, a 4% increase year-over-year, driven by double-digit growth in Pain Treatments. GAAP earnings per diluted share improved to $0.47 from $0.11, aided by the removal of a $24.6 million deferred tax valuation allowance and lower interest expense following a $20.0 million term loan prepayment. The company reaffirmed its full-year 2026 guidance for net sales between $600 million and $610 million. Concurrently, Bioventus announced it has initiated a review of strategic alternatives, including a potential sale, after receiving an unsolicited acquisition proposal and other expressions of interest from third parties. The Board established a committee of independent directors to evaluate these options with the assistance of Evercore and Latham & Watkins. Bioventus Inc. operates in the medical device industry, providing innovations for active healing such as pain treatments, surgical solutions, and restorative therapies.